vnP，PCAOejection，）、、P（（two）]MODERN。）si。、（withfailurepatients（，）]ds）on]，（，-。DecemberXIELI、ZHOU、no、w）l（exercise）to。）to（）。（，，）Mete、·ectn·PnPtwou′o，LUO。Jiancl、LIfraction）preservedtwo（）sheartwitht、inResutrainingrehabilitationof，effect-nn（a（-P（our。[Keytonoh（[~；-，-，[R，[i、，，；MEDICINE，rds]P）o（。（P）jOb），，（，n，]ct）。。rast；s
2018 12 25 34
529600
[ ] HFPE F 2016 1
2017 1 100
=50 =50
NT-proBNP 6 min
6MWD / LAVI E / A
>0 .05
<0.05
NT-proBNP LAVI 6MWD E/A NT-proBNP
LAVI 6MWD E/A <0.05
<0.05
[ ]
541 A 1674-4721 2018 12 -0060-03
Applicatio
Bing-jie Yu-mei Xiang-wei Zong-ming Rui-juan
Ward Two of Department of Cardiology, Yangchun People Hospital, Guangdong Province, Yangchun 529600, China
[Ab To explore the effect of exercise rehabilitation training patients with heart failure with pre
served ejection fraction (HFPEF). A total of 100 patients with heart failure admitted hospital from Jan
uary 2016 January 2017 were enrolled as subjects. The ejection fractions were all preserved and divided into control
group ( =50) and experimental group ( =50) according computer randomization. In the the control group, routine
treatment and nursing were provided, while in the experimental group, exercise rehabilitation training was added. The
blood pressure (diastolic and systolic blood pressure), resting heart rate, plasma sodium cerebral peptide (NT-proBNP)
before and after the intervention, the walking test distance was 6 min (6MWD), left atrial volume/body surface area
(LAVI), early diastolic blood flow rate (E)/late diastolic blood flow rate (A) and rehospitalization rate were compared be
tween the groups. There was significant difference in blood pressure between the groups before and
after treatment ( >0.05). The resting heart rate of the groups were lower than those before treatment, the resting
heart rate of the experimental group was lower than that of the control group after treatment, the differences were statis
tically significant ( <0.05). The NT-proBNP and LAVI levels after therapy were lower compared with those before
treatment, the 6MWD and E/A levels were higher than those before treatment, and the levels of NT-proBNP and LAVI
in the experimental group were lower than those of the control group, and the levels of 6MWD and E/A were higher
than those of the control group, the differences were statistically significant ( <0.05). The rehospitalization rate in the
experimental group was significantly lower than that in the control group, and the difference was statistically significant
(<0.05).Co Patients with HFPEF receiving exercise rehabilitation training can effectively increase their exer
cise tolerance, reduce the rehospitalizationrate, and improve their prognosis.
Exercise rehabilitation training; Ejection fraction; Heart failure
HFPEF
[1-2]
HFNEF
60 CHINA Vol. 25 No. 34 2018，±（，、~，、±④、，（），Decemberm①。。]，，~（g，，，，、。③），①）、、；[，in，，；mmm，~。，）m，（）、p（P（、、（、β；R±，，·；in，，~）~）P②n、（）n、i，（x，。。，（、MODERN~m：，m，（，，；、To）in，、、±（。。SS，±；±。，、。、、、±②±±±，Pt，mg、③。P；：。，，P，⑤，。），s~m，。。（。）·n）~。、m（，in，（，±±in）；inP~CHINA③（±）P）；，m，，、。，，，in；①，~P（±，g）MEDICINE；~、（，±）；±，[]±P。②、、、rP、m（W），（V）±；±β，。（）。SP：xs，t。χ，、P，、、，P），
2018 12 25 34
60~ 80 /m
3-4
HFEF 1 2
34 15
100 20 4
HFEF
1 10~ 15 /m
1.1 35 20 40
2016 1 2017 1 4
100 HFEF
HFEF 35 30
2 2~ 3 40 12 HFEF
5
1.3
=50
=50 30 20 46 N-BN 6
67 56.636.01 1 8 4.23 6MD / LAI
1.06 29 3 21 2 E / A
32 18 4568
56.596.15 17 4.301.09 30 1.4
3 2 2 21.0
2
> 0.05
<0.05
2
1.2 2.1
> 0.05
A B A CEI
130/80 H <0.05 1
1
H H /
50 124.10 18.56 125.12 19.20 71.23 10.70 70.7810.40 76.5812.63 65.5210.12
50 125.09 19.32 126.01 17.81 70.15 11.35 70.6711.25 76.01 11.41 71.56 9.52
0.2613 0.2403 0.4896 0.0508 0.2368 3.0739
0.7944 0.8106 0.6255 0.9596 0.8133 0.0027
<0.05
Vol. 25 No. 34 2018 61）、，s、。。），，V[rNT[]V，，r，±[）l±P。。6MW，，p]，P]。（，（RpT（。，n，（W），±、，、，，PTproBNP、[rPTo，、·[（P，±P±，，]WPP，）±V（：P，，：To、r）]，，PrP，（P（m，、t、、[。x，，±、]，P，（±，、DLAVIEA。。Tpo、，，r，P±V。P。，，±W±、V，：±T，po、、W。，±）（，，，，P）P）S）、，]）orP），p±（，，。，；，）T（。po（，g，，m）±χ，、，mW。V，（P），、，、，、]、，、（，，±）±[V]]、o，，p（[，]P，·
2018 12 25 34
2.2 - / N-BN LAI
N-BN LAI 6MD E/A
6MD E/A <0.05 2
2 NT-proBNP 6MWD LAVI E/A
N-BN / 6MD LAI E/A
50 579.12 126.30 275.69 103.65 324.58 112.58415.85112.58 47.85 10.51 32.58 8.71 0.710.09 0.96 0.08
50 575.63105.42 416.21123.02 330.25 102.36 362.56110.52 46.81 11.03 39 .759.45 0.720.08 0.81 0.09
0.1500 6.1768 0.2635 2.3885 0.4827 3.9450 0.5872 8.8083
0.8811 0.0001 0.7927 0.0188 0.6304 0.0002 0.5584 0.0001
<0.05
2.3
1 12.00% 6/50
14
1 38.00% 19/50
2
=
9.0133 =0.003
3
HFEF
15-20
6-7
>0.05
HFEF
8
N-BN
<0.05 N-BN LAI
9
6MD E/A
LAI HFEF
N-BN LAI
6MD E/A
LAI
<0.05
HFEF
<0.05
10-11
HFEF
AA
N-BN E/A
[1 .6
12-13
[J]. 2013 35 1 17-20.
[2 .
[J]. 2016 45 12
1627-1628 1631.
[3 .
[J].
2017 5 29 104.
62 CHINA MODERN MEDICINE Vol. 25 No. 34 December 2018，．meta，，of，，]（[，sive（，bypass：．，December（trials，]：：]，：）the，：assessed）physon）]（heart，，]（ran：，]，（（，，）），），，ascending，：，，artery），，withlong，anddoppler：，（coronary，for），：，analysis，，）domized·]，，：：：），，]，，），（：，，）（elasticity，，of，：in）MODERN：-，，，heart，m：postoperative]，，safety，echocardiography，off，-：，，versus，）：artery，，，grafting（）：coronary，disease：，a，：），，for，（）-：controlled，．][，[]，[，（），，，：，），，（，（，）：：，（、]（，（，·，（，））、：）]（（of，aorta（：and）CHINAseverity（，，coronary，stenosis（，，（hyperten：（）），patients，，coronaryanddiseaseMEDICINEby，（，），tissue，（：，，（）：]，，]，（），）：
2018 12 25 34
[4 . 973-979.
[13 .
[J].
[J]. 201839 2 30-
2017 32 11 1099-1103.
33.
[5 .
[14 .
[J]. 2015 24 5
[D]. 2015.
501-504.
[15 .
[6] .
-1 [J].
[J].
2015 24 1 5-9.
201840 2 111-115.
[16] .
[7] .
[J].
[J].
2017 16 19 1918-1922.
2014 11 7 8-10.
[17] . [J]. 2016 28
[8 .
3 297-299.
[J]. 2016 184 373-376.
[18 .
[9] .
[J]. 2016 28 5
[J]. 2015 44 24 3370-
670-673.
3373.
[19] .
[10] .
[J].
J.
2017 16 15 1480-1483.
2017 32 11 1099-1103.
[20] .
[11] . [J].
J.
2015 24 4 356-359.
201817 8:8 06-810.
[12 .
2018-07-09
J. 201531 6
59
[11] . VEGF [J].
[J]. 2017 14 3 178-180.
2014 49 12 1377-1379. [16] .
[12]Luo TB Ni YM.Short-term -term [J].
-pump -pump 2016 23 33 37-39.
- [17] .
J.Thorac Cardiovasc Surg 2015 [J].
63 4 319-327. ,2017 29 12 1770-177 3.
[13]Lu Q Liu H.Correlation [18 .
[J]. 2016 284 528-533.
-mode [19] .
[J].Cell Biochem Bio [J].
2015 71 2 785-788. 2017 29 7 978-981.
[14 [20] .
[J] 2016 [J].
24 5 129-131 2016 54 7 69-71.
[15 . 2018-06-21
Vol. 25 No. 34 2018 63 |
|
